Acute leukemia can be diagnosed when blasts constitute 30% or more of the nucleated cells in a patient 's peripheral blood (PB) In the light of soaring health care costs, the diagnostic usefulness of costly and painful BM aspirates and biopsies for patients with acute leukemia who have high numbers of PB blasts is questionable. BM aspiration studies routinely are performed on these patients, and the need for these studies is undocumented. We therefore investigated the need for BM aspirates in 49 patients with PB blast counts of 30% or more. We compared the results of morphologic, cytochemical, immunophenotypic, and cytogenetic studies of PB and BM aspirate samples (not all studies were performed for all 
In 1976, the French-American-British (FAB) Cooperative Group proposed the FAB classification system for acute leukemias. 1 The system was modified in 1981 2 and in
1985
. 3 The FAB classification of acute leukemia is based on the presence of 30% or more blasts in bone marrow (BM) specimens and on other morphologic and cytochemical criteria. In 1989, Cason et al 4 proposed the term peripheral acute leukemia for patients with peripheral blood (PB) blast counts of 30% or more and BM blast counts of less than 30% whose clinical and cytogenetic characteristics are compatible with acute myeloid leukemia (AML). This was incorporated into the acute leukemia classification by the National Cancer Institute-sponsored Workshop on Definitions of Diagnosis and Response in Acute Myeloid Leukemia in 1990. It was recommended that the diagnosis of AML be made when the percentage of blasts in PB samples is 30% or more, even if the blast count in the BM is less than 30%. 5 In the light of soaring health care costs, the diagnostic usefulness of costly and painful BM aspirates and biopsies for patients with acute leukemia who have high numbers of PB blasts is questionable. BM aspiration studies routinely are performed on these patients, and the need for these studies is undocumented. We therefore investigated the need for BM aspirates in 49 patients with PB blast counts of 30% or more. We compared the results of morphologic, cytochemical, immunophenotypic, and cytogenetic studies of PB and BM aspirate samples (not all studies were performed for all PERIPHERAL BLOOD AND BONN MAAROW IN LEUKEKIA DIAGNGSIS patients). To gain more cytogenetic information, the growth of PB blast cells was stimulated with human granulocytemacrophage colony-stimulating factor (GM-CSF) 6 in a subgroup of 15 patients.
Materials and Methods

Patients
About 35% of patients with newly diagnosed leukemia examined at the acute leukemia clinic at The University of Texas M.D. Anderson Cancer Center, Houston, have PB blast counts of 30% or more. In 30 of these patients (patients 1-30) liable II, the morphologic features, cytochemical staining, and immunophenotype were prospectively compared in PB and BM samples, while the cytogenetics in PB and BM samples were prospectively compared for 25 of the 30 patients and for another 19 patients (patients 31-49) liable 21. The patients were between 1 and 80 years of age. The diagnoses were made from PB samples, BM aspirates, and biopsy specimens according to the FAB classification of acute leukemias. 7 Fourteen patients had acute lymphoblastic leukemia (ALL; 2 had relapsed ALL), 30 had AML (8 had relapsed AML), 4 had chronic myelogenous leukemia (CML) in blast crisis, and 1 had plasma cell leukemia (PCL).
Cytochemistry
Cytochemical and immunohistochemical staining was performed according to routine protocols [8] [9] [10] and included
Wright-Giemsa, periodic acid-Shiff reaction," Sudan black B, 12 myeloperoxidase, 13 oc-naphthyl butyrate esterase, 14 tartrate-resistant acid phosphatase, 15 and terminal deoxynucleotidyl transferase (TdT)1 6 staining.
Immunophenotyping
Flow cytometry studies were performed on PB samples of patients 1 through 30 (Table 11) No BM samples from patients 11 and 12 were submitted for flow cytometric analysis. Monoclonal antibodies against the following antigens were used: CD13, CD33, CD34, CD14, CD64, CD10, CD19, TdT, CD2, CD7, and CD41. 17 For selected patients, the following additional monoclonal antibodies were used:
• PB-ABC = peripheral blood absolute blast count; BM = bone marrow; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML-BC = blast crisis of chronic myelogenous leukemia; PCL = plasma cell leukemia. * The designations accompanying ALL and AML diagnoses indicate the French-American-British classification.
• PB-ABC = peripheral blood absolute blast count; BM = bone marrow; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; ERY + BL = erythroid cells and blasts; CML-BC = blast crisis of chronic myelogenous leukemia. * The designations accompanying ALL and AML diagnoses indicate the French-American-British classificatton.
an antibody against surface immunoglobulin (for patients [1] [2] [3] [4] [5] [6] [7] [8] , an antibody against CD4 and CD8 to confirm T-cell ALL (for patients 1 and 6), and antr-CD38, anti-plasma cell antigen, and CD138 antibodies (for patient 30, who had PCL.) Tricolor flow cytometry analysis was performed by using a standard whole blood lysis technique. First, 0.5 to 1 x 10 6 cells were chilled for 10 minutes at 2°C to 8°C. After incubation, the erythrocytes were lysed in NH 4 C1 for 5 minutes. Two washing steps using phosphate-buffered saline solution followed. The stained cells were fixed with 1% paraformaldehyde. Flow cytometric analysis was performed (FACScan, Becton Dickinson, Mountain View, CA), and the data were evaluated with LYSIS II software (Becton Dickinson). Blasts were gated based on side scatter and CD45 antigen expression. The results were expressed as the percentage of cells expressing the antigen.
Cytogenetic Analysis
BM aspirates and unstimulated PB samples were incubated overnight at 37°C in Ham's F-10 medium (GIBCO, Grand Island, NY), supplemented with L-glutamine (GIBCO), vitamins (GIBCO), 10% fetal bovine serum (Armour Pharmaceuticals, Kankakee, IL), and penicillin and streptomycin (GIBCO). Cultures were harvested and slides prepared by established methods. 18 At least 20 metaphases of Giemsa-banded BM samples and 10 metaphases of PB samples were analyzed by using routine procedures. GM-CSF (Sargramostim, Leukine, Immunex, Seattle, WA) was dissolved in 2.5 mL of phosphate-buffered saline. Ten microliters of this solution was added to each 10 mL of PB sample. The GM-CSF-stimulated PB samples were then cultured side by side with unstimulated PB samples for 72 hours at 37°C in RPMI 1640 (GIBCO), supplemented with 10% fetal bovine serum (Armour Pharmaceuticals), L-glutamine (GIBCO), vitamins (GIBCO), and penicillin and streptomycin (GIBCO). The BM samples were incubated for 24 hours at 37°C in RPMI 1640 (GIBCO) supplemented with 10% fetal bovine serum (Armour Pharmaceuticals), L-glutamine (GIBCO), vitamins (GIBCO), and penicillin and streptomycin (GIBCO). Karyotyping was performed on 2 metaphases per clone as described in the previous paragraph.
Results
Similar Morphologic Features and Cytochemical Staining of BM and PM Blasts
• with blast counts of 30% or more can be used for diagnosis according to the FAB criteria, instead of using BM aspirates.
Similar Immunophenotyping Between PB and BM Blasts
The PB and BM samples were analyzed with a panel of antibodies for markers of blast lineage determination (CD 13, CD33, CD34, CD10, CD19, TdT, CD2, and CD41). 17 Other markers, such as CD64, c-kit, 21, 22 CD4, CD8, CD7, CD38, plasma cell antigen, CD 138, and glycophorin A, were included when considered necessary for the diagnosis. Overall, there were no immunophenotype differences between PB and BM blasts. Correlation between surface marker expression in PB and BM was tested by using the Spearman rank correlation test. 23 1 Table 41 shows distribution of values for selected surface markers. There was very strong correlation between PB and BM results (P < .001). A discrepancy between BM and PB was seen in CD33 expression in 2 patients (patients 3 and 4) with ALL; they had 46.2% and 85.9% expression, respectively, in PB but only 15.9% and 1.4%, respectively, in BM. However, this discrepancy did not alter the diagnosis. A discrepancy in CD64 expression was noted in patient 19 (AML, M4), whose CD64 expression in the PB sample was very low (2.1%), but expression in the BM aspirate was positive (34%). The PB monocyte count for patient 19 was 12%, whereas the BM monocyte count was 3%. BB4 and monoclonal antibodies against CD4, CD8, CD38, PCA, glycophorin A, and surface immunoglobulins, which were used in selected cases, showed similar expression in PB and BM samples (results not shown).
Difference Between PB and BM Cytogenetic Analyses
PB and BM samples for cytogenetic analysis were obtained for 44 patients showing blast counts of 30% or more in PB samples. ITable 51 gives the cases in which a discrepancy between the PB and BM findings was noted. Twelve of the patients had ALL, 29 had AML, 2 had CML in blast crisis, and 1 had PCL. No mitotic cells were recovered from the PB or BM specimen in 1 case (patient 2). Ten samples • 1.0 10.0 * Peripheral blood (PB) and bone marrow (BM) specimens were studied for each patient. The data are given as percentiles, eg, for CD 13, 25% of PB specimens had values <24.8, 50% had values <77.7, and 75% had values <97.1. For all comparisons, P < .001 (f test, Spearman rank correlation).
• [11] 45-46,XX,del(1)(q21),-3,-4,del(5)(q15),+add (7)(q36) del (11) GM-CSF = granulocyte-macrophage colony-stimulating factor; ALL = acute lymphoblastic leukemia; ND = not done; AML = acute myeloid leukemia. * The designations accompanying ALL and AML diagnoses indicate the French-American-British classificatton.
(23%) had an insufficient number of metaphases for analysis when PB but not BM was the source of blasts, whereas the inverse (insufficient in BM but not PB) never occurred. Five of the 10 had ALL, which was 41% of all patients with ALL included in the study. Only 5 (17%) of 29 patients with AML had an insufficient number of PB metaphases for analysis. There was no correlation between the number of blasts and the number of analyzable metaphases.
To determine whether addition of growth factors to PB cultures improves cytogenetic yield, the PB samples of 15 patients also were cultured with GM-CSF for cytogenetic analysis. Five of the 15 PB samples (patients 35, 36, 39, 42, 48) without GM-CSF yielded insufficient metaphases. For patients 36 and 38, the treatment of PB with GM-CSF permitted recovery of sufficient metaphases for analysis, and results were consistent with the results of BM analysis. To Wemkaiitt et al /PERIPHERAL BLOOD AND BONE MARROW IN LEUKEMIA DIAGNOSIS examine whether there is a difference in the karyotypes from PB and BM cells, the cytogenetic abnormalities found were placed into 4 groups according to their prognostic significance: 24 was used to test the hypothesis of no difference between PB and BM cytogenetic results. The ratio of "ties" (PB and BM assigned to the same category) to "nonties" (PB and BM assigned to different categories) was 30:14 if insufficient PB yield was counted as a nontie. The P value for the hypothesis of no difference between PB and BM was 0.18. 18 When the insufficient yield group was excluded from the nonties, the tie/nontie ratio increased to 30:4, suggesting a highly significant concordance between the cytogenetic results for PB and BM. The remaining 4 nonties were for patients 4, 7, 23, and 44, whose PB karyotypes failed to reveal an important cytogenetic abnormality with good recovery from the corresponding BM sample.
Discussion
Traditionally, BM aspirates were the preferred tissue for the diagnosis of acute leukemias. However, the inconvenience of this procedure and the economic considerations might dictate less frequent use of the procedure if it could be demonstrated that PB samples gave consistent results. Because a 30% blast count in PB has been considered adequate for the diagnosis of acute leukemia or the blast crisis of CML, we evaluated how the final diagnosis would be influenced if PB were to replace the BM aspirate and biopsy as a source of diagnostic material.
Approximately 35% of patients with leukemia examined at the acute leukemia clinic at The University of Texas M.D. Anderson Cancer Center have blast counts of 30% or more in their PB samples. To determine whether the diagnosis of acute leukemia according to the FAB criteria could be made from PB samples instead of BM aspirates, we performed comprehensive morphologic and cytochemical analysis of PB and BM samples from 30 patients, including 16 with AML, 10 with ALL, 3 with CML in blast crisis, and 1 with PCL ( Table 1) . The morphologic and cytochemical features of PB and BM blasts were similar, as were the percentages of myeloperoxidase and Sudan black B positivity. Some cases showed a higher percentage of myeloperoxidase positivity in PB samples than in BM aspirates (eg, patient 16), and some showed a higher percentage in BM (eg, patient 19). Comparison of the results revealed that BM can be replaced by PB as a source of blasts for morphologic and cytochemical analysis in patients with a blast count of 30% or more in the PB sample. The only drawback to using PB is the inability to distinguish between Ml and M2 cases as defined by the FAB classification. M2 is the presence of maturation to promyelocytes and more mature cells in 10% or more of the cells in the BM. Distinguishing between Ml and M2 is of dubious relevance.
Similar results were obtained by immunophenotyping the PB and BM samples. The flow cytometry results obtained for 30 patients with an average of 15 markers showed a high degree of concordance (Table 4) . A high correlation also was noted in cases in which additional monoclonal antibodies were used to confirm the diagnosis. Overall, there was no significant difference in immunophenotype between PB and BM blasts (Table 4 ). Based on the results for the 30 patients, we conclude that PB samples can be used for the diagnosis of acute leukemia.
However, we observed a difference in the number of analyzable metaphases in cytogenetic studies performed on the PB and BM samples. Ten of 40 PB samples (25%) yielded insufficient metaphases for analysis. When these cases were excluded and the karyotypes obtained from the PB and BM samples of the remaining cases compared, only 3 PB samples showed minor discordance with the BM aspirates. In 1 case, ,n the PB samples, only 1 metaphase with an abnormal clone was shown instead of 2 as required for defining an abnormal clone (patient 9); patient 26 had t(13;18) in the BM aspirate but not in the PB sample; and patient 38 had -17 in the BM sample. Interestingly, of the 10 samples with insufficient PB metaphases for analysis, 5 patients had ALL, which is 41% of all patients with ALL in the study. In contrast, 17% of patients with AML had insufficient PB yields, which suggests that the probability of an insufficient cytogenetic harvest is higher in ALL than in AML.
To test whether the addition of growth factors could improve PB cytogenetic yield, we cultured 15 PB samples with and without GM-CSF. Of the 5 PB cultures with inadequate metaphases, 2 yielded a sufficient number of metaphases when grown in GM-CSF, suggesting that growth factors may improve the yield for cytogenetic studies on PB samples. Maeda et al 29 showed a difference in karyotype between PB and BM cells in a patient with CML in blast crisis. In a more recent article, a discrepancy in 20q deletions in PB and BM samples was reported for patients with myelodysplastic and myeloproliferative syndromes. 30 All these studies were hampered by the low metaphase yield. Molecular studies also have shown differences between PB and BM blasts in some patients. Beishuizen et al 31 analyzed paired BM and PB samples from 30 patients with precursor B-ALL for the configuration of their immunoglobulin heavy chain and immunoglobulin K chain genes. In 5 cases (17%), the differences in gene rearrangements in the BM and PB samples were detected. In all 5 cases, the extra subclones or the relatively larger subclones were found in the BM samples, suggesting that subclone formation in precursor B-ALL occurs in the tissue compartment from which the precursor B-ALL cells are thought to originate. This phenomenon will lead to underestimation of subclone formation if only immunoglobulin heavy chain gene analysis of PB samples is performed.
The data we present suggest that a PB sample with a blast count of 30% or more is adequate for the accurate diagnosis of acute leukemia. Therefore, BM aspirates are unnecessary for diagnosis. However, in some cases, BM aspirates likely will be needed to determine the leukemia cell karyotype. If treatment can be delayed and if cytogenetic analysis can be done within 1 week, it would be reasonable to forego BM until it is known whether the PB sample yielded a sufficient number of metaphases. Recent advances and the availability of molecular tests make it possible to use PB samples to detect most of the clinically significant molecular abnormalities, including t(15;17), t(9;22), t (8, 21) , t(4;ll), t(9;ll), and invl6 by Southern blot or reverse transcription-polymerase chain reaction analysis. 
